| Literature DB >> 26267537 |
Lei Wang1, Yang Yu1, Dar-Chone Chow2, Fei Yan1, Chih-Chao Hsu3, Fabio Stossi1, Michael A Mancini1, Timothy Palzkill2, Lan Liao1, Suoling Zhou1, Jianming Xu1, David M Lonard4, Bert W O'Malley5.
Abstract
By integrating growth pathways on which cancer cells rely, steroid receptor coactivators (SRC-1, SRC-2, and SRC-3) represent emerging targets in cancer therapeutics. High-throughput screening for SRC small molecule inhibitors (SMIs) uncovered MCB-613 as a potent SRC small molecule "stimulator" (SMS). We demonstrate that MCB-613 can super-stimulate SRCs' transcriptional activity. Further investigation revealed that MCB-613 increases SRCs' interactions with other coactivators and markedly induces ER stress coupled to the generation of reactive oxygen species (ROS). Because cancer cells overexpress SRCs and rely on them for growth, we show that we can exploit MCB-613 to selectively induce excessive stress in cancer cells. This suggests that over-stimulating the SRC oncogenic program can be an effective strategy to kill cancer cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26267537 PMCID: PMC4536575 DOI: 10.1016/j.ccell.2015.07.005
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743